Skip to main content
. 2019 Nov 15;9:1189. doi: 10.3389/fonc.2019.01189

Figure 6.

Figure 6

Impact of MUS81 suppression on the anti-tumor activity of CPT. (A) Representative whole-body coronal micro-PET CT images of BALB/c mice bearing SOC 1 h after intravenous injection of 18F-FDG (1.85 MBq/mouse) on day 14 after inoculation or day 7 after treatment initiation. Tumors are indicated in the circles. (B) Tumor volumes were measured in the CON and MUS-KD groups (n = 6, respectively); line graph shows average tumor size in mice. (C) Evidence of increased chemotherapy sensitivity of tumors with reduced MUS81 levels using the micro-PET CT and the imaging reagent FLT. The 20-day tumor bearing mice in two groups (n = 6, respectively) were injected CPT (10 mg/kg) on d 3, 6, and 9; representative whole-body coronal micro-PET CT images of mice with SOC 1.5 h after intravenous injection of 18F-FLT (1.85 MBq/mouse) on day 12. (D) Quantitative ROI analysis of tumor uptake from 18F-FLT micro-PET CT. (E) Inhibition of MUS81 reduced tumor volumes and liver metastasis. Transduced SKOV3 cells were injected intraperitoneally to make a BALB/c mice SOC tumorigenesis model. Tumors were scanned by Micro-MR imaging (I). Representatives of liver metastasis of tumors in MUS-KD group and CON group (arrow represents the site of metastasis) (II).